HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

von Hippel–Lindau protein promotes Skp2 destabilization on DNA damage

(2011) J-S Roe et al.   ONCOGENE

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

(2010) V. V. Leshchenko et al.   BLOOD

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma

(2010) R. Shaknovich et al.   BLOOD

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies

(2010) E. Marchi et al.   CLINICAL CANCER RESEARCH

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

(2010) Frederick Lansigan et al.   DRUGS

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

(2010) Cliona Grant et al.   Expert Review of Anticancer Therapy

Therapy with azanucleosides for myelodysplastic syndromes

(2010) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia

(2009) M. Kanduri et al.   BLOOD

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Current status of epigenetic treatment in myelodysplastic syndromes

(2008) Andrea Kuendgen et al.   ANNALS OF HEMATOLOGY

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas

(2008) K. Amara et al.   ANNALS OF ONCOLOGY

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

(2008) L. Paoluzzi et al.   BLOOD

Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies

(2008) Alessandro Pavan et al.   LEUKEMIA & LYMPHOMA